UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q or (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of incorporation or organization)(I. ...

For the quarter ended September 2024, Amgen (AMGN) reported revenue of $8.5 billion, up 23.2% over the same period last year. EPS came in at $5.58, compared to $4.96 in the year-ago quarter.The reported revenue represents a surprise of -0.04% over the Zacks Consensus Estimate of $8.51 billion. With the consensus EPS estimate being $5.11, the EPS surprise was +9.20%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their nex ...

Amgen (AMGN) came out with quarterly earnings of $5.58 per share, beating the Zacks Consensus Estimate of $5.11 per share. This compares to earnings of $4.96 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.20%. A quarter ago, it was expected that this world's largest biotech drugmaker would post earnings of $4.93 per share when it actually produced earnings of $4.97, delivering a surprise of 0.81%.Over the last four quarters ...

Exhibit 99.1 One Amgen Center Drive Thousand Oaks, CA 91320-1799 | --- | --- | |--------------|----------------------------------------| | | | | News Release | Telephone 805-447-1000 www.amgen.com | AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS THOUSAND OAKS, Calif. (Oct. 30, 2024) - Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024. "Strong growth in sales and earnings this quarter reflects the momentum we're building throughout our business. We continue to invest hea ...

THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024. "Strong growth in sales and earnings this quarter reflects the momentum we're building throughout our business. We continue to invest heavily in our rapidly advancing pipeline, with a focus on delivering innovative therapies across our core therapeutic areas," said Robert A. Bradway, chairman and chief executive officer. Key results include: For the third quarter, total r ...

Core Insights - The article discusses the benefits of investing in dividend stocks, highlighting Visa and Amgen as strong candidates for long-term investment due to their business models and growth potential. Visa - Visa operates a leading payment processing network that connects merchants and banks, allowing for smooth transaction flows without credit risk as it does not issue cards or extend loans [2]. - The company earns fees from millions of daily transactions, benefiting from high gross and net margins due to low incremental operating costs for additional transactions [2][3]. - Visa enjoys a competitive advantage through network effects and a strong brand, making it difficult for competitors to gain market share [3][4]. - The company has significant growth potential as it captures a larger share of the global payments market, especially in developing countries where cash and check payments are still prevalent [4]. - Visa's dividends have increased by 333% over the past decade, with a forward yield of 0.7% and a cash payout ratio of just under 22%, indicating room for further dividend increases [5]. Amgen - Amgen is a leading drugmaker with a strong track record of innovation and a portfolio of over two dozen medicines, several generating more than $1 billion in annual sales [6]. - The company has expanded its product lineup through acquisitions, including the $28 billion purchase of Horizon Therapeutics, enhancing its portfolio with Tepezza, a therapy for thyroid eye disease [6][7]. - Amgen is actively developing new compounds, including a promising weight loss medicine called MariTide, supported by its financial resources and industry experience [7]. - The company reported a revenue increase of 40.51% and a net income increase of 30.22%, with a dividend growth of 268.9% [8]. - Amgen's forward yield is nearly 2.9%, with a cash payout ratio of 86%, reflecting its commitment to rewarding shareholders despite recent acquisitions [8].

THOUSAND OAKS, Calif., Oct. 25, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The dividend will be paid on December 9, 2024, to all stockholders of record as of the close of business on November 18, 2024. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there. I last covered Amgen (NASDAQ: AMGN ) for Seeking Alpha in early August, reviewing the California based Pharma giant's Q2 earnings. I gave its stock a "Buy" rating, however ...

Analysts on Wall Street project that Amgen (AMGN) will announce quarterly earnings of $5.11 per share in its forthcoming report, representing an increase of 3% year over year. Revenues are projected to reach $8.52 billion, increasing 23.4% from the same quarter last year. The consensus EPS estimate for the quarter has undergone a downward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates duri ...

THOUSAND OAKS, Calif., Oct. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.Live audio of the conferenc ...